Nuvation Bio and Eisai's Taletrectinib Application for NSCLC Accepted by EMA

The European Medicines Agency (EMA) has accepted the application from Nuvation Bio and Eisai for taletrectinib, a drug intended for the treatment of non-small cell lung cancer (NSCLC).